Notice of Half-Year Financial Results
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
TURKU, Finland - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, will report its unaudited half-year financial results for the six months ended June 30, 2024, on Tuesday, 27 August 2024.
A live hybrid briefing and Q&A session for investors, analysts and media will be hosted by Dr. Juho Jalkanen, Chief Executive Officer, and Yrjö Wichmann, Chief Financial Officer, at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on Wednesday, 28 August 2024.
Webcast registration link: https://faron.videosync.fi/q2-2024
Live participation
In addition to the webcast, there are a number of spaces available to attend the briefing in-person at Studio Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To register, please contact
investor.relations@faron.com no later than 10:00 a.m. EEST on Monday, 26 August 2024. Please note that places are limited, and you will receive a separate email confirmation.
The half-year report, presentation, and a replay of the webcast will be available on the Company's website at www.faron.com/investors.
About Bexmarilimab
About Faron Pharmaceuticals Ltd.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.